timolol palmitate

Timolol palmitate is a lipophilic prodrug of the non-selective beta-adrenergic antagonist timolol, specifically engineered for the long-acting treatment of glaucoma and ocular hypertension. By esterifying timolol with palmitic acid, the molecule is capable of self-assembling into colloidal drug aggregates (CDAs). In experimental formulations, these CDAs are incorporated into an in situ gelling hyaluronan-oxime hydrogel for subconjunctival injection. This delivery system provides a sustained release of the active drug, maintaining reduced intraocular pressure for significantly longer durations (e.g., over 49 days in animal models) compared to standard timolol maleate eye drops. Additionally, the prodrug approach minimizes systemic absorption, potentially reducing the risk of cardiovascular and respiratory side effects associated with systemic beta-blockade.